Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: OpGen Inc

Market Cap 43.34M 37.87M 35.03M 32.7M 61.39M 4.1B 61.84M 416M 162M 2.01B 163M 159M 7B P/E 2024
0.26x
P/E 2025 6.86x
Enterprise Value 44.66M 39.02M 36.1M 33.69M 63.25M 4.22B 63.71M 429M 167M 2.08B 168M 164M 7.21B EV / Sales 2024
1.29x
EV / Sales 2025 5.39x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 50 01/12/2025
Chief Tech/Sci/R&D Officer 37 01/04/2025
Chief Operating Officer 54 04/12/2024
Director TitleAgeSince
Chairman 36 02/08/2024
Director/Board Member 39 09/08/2024
Director/Board Member 40 09/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
+21.45%+1,817.73% - - 6.39M
+2.26%+3.44%-8.84%-3.47% 43.24B
+1.73%+3.59%+318.08%+564.04% 35.25B
+0.61%+1.34%+10.00%+46.20% 30.22B
+0.02%-5.93%+8.45%-21.44% 28.01B
-1.06%-3.71%+9.08%+19.56% 24.08B
-1.23%+2.11% - - 14.16B
-0.99%-2.53%+47.29%+102.88% 13.01B
+2.30%+3.57%+9.14%+14.81% 12.7B
+2.39%+2.61%+102.86%+84.20% 12.54B
Average +2.75%-0.27%+62.01%+100.85% 23.69B
Weighted average by Cap. +0.85%-0.20%+68.37%+118.47%

Financials

2024 2025
Net sales 5.2M 4.54M 4.2M 3.92M 7.36M 491M 7.41M 49.91M 19.42M 241M 19.51M 19.09M 839M 30.2M 26.39M 24.41M 22.78M 42.77M 2.85B 43.08M 290M 113M 1.4B 113M 111M 4.87B
Net income 11.99M 10.48M 9.69M 9.05M 16.98M 1.13B 17.11M 115M 44.82M 557M 45.03M 44.05M 1.94B 23.62M 20.64M 19.09M 17.82M 33.45M 2.23B 33.7M 227M 88.27M 1.1B 88.68M 86.76M 3.81B
Net Debt 711K 621K 575K 536K 1.01M 67.19M 1.01M 6.83M 2.66M 33.03M 2.67M 2.61M 115M 1.32M 1.15M 1.06M 993K 1.86M 124M 1.88M 12.65M 4.92M 61.17M 4.94M 4.84M 213M
Logo OpGen Inc
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!